mAbs

First-in-Class

First-in-Class mAbs

First-in-Class Monoclonal Antibodies

Pipeline

PBP1510
(Ulenistamab)

Category

Monoclonal
Antibody

Indication

Pancreatic cancer,
Ovarian cancer

Development Stage

  • Phase 1/2a Clinical Trial in Europe and U.S. 50% 50%

Pipeline : PBP1510 (Ulenistamab)

Category : Monoclonal Antibody

Indication :
Pancreatic  cancer, Ovarian cancer

Development Stage

  • Phase 1/2a Clinical Trial in Europe and U.S. 50% 50%

Pipeline

PBP1710
(Anti-CTHRC1)

Category

Monoclonal
Antibody

Indication

Solid Tumors

Development Stage

  • Prearing For preclinical trial 25% 25%

Pipeline : PBP1710 (Anti-CTHRC1)

Category : Monoclonal Antibody

Indication : Solid Tumors

Development Stage

  • Prearing For preclinical trial 25% 25%

Improving Accessibility & Affordability of Existing Biological Drugs

Prestige Biopharma aims to expand patient access to treatment by providing safe, quality and affordable biomedicines. Our biosimilar portfolio consists of 12 pipelines, including our HD201 (trastuzumab) in completion of Phase III, HD204 (bevacizumab) in Phase III and PBP1502 (adalimumab) in Phase I.

Our groundbreaking accomplishments

Biosimliar Pipeline

first-In-Class